BACKGROUND AND AIM OF THE STUDY: Contemporary tissue valves are non-viable, and unable to grow, repair or remodel. It was postulated that tissue-engineered heart valves (TEHV) fabricated from autologous cells and a biodegradable scaffold could yield a dynamic progression of cell phenotype and extracellular matrix (ECM), in vitro and in vivo, and ultimately recapitulate native valve microscopic architecture. METHODS: Trileaflet valve constructs were fabricated from poly-4-hydroxybutyrate-coated polyglycolic acid seeded with ovine endothelial and carotid artery medial cells, cultured in vitro for 4-14 days in a pulse duplicator, implanted as pulmonary valves in five lambs, and explanted at 4-20 weeks. ECM composition and collagen architecture were examined by histology (including Movat pentachrome stain and picrosirius red under polarized light), and cell phenotype by immunohistochemistry. RESULTS: Cells from in-vitro constructs (14 days) were activated myofibroblasts, with strong expression of alpha-actin (microfilaments), vimentin (intermediate filaments) and SMemb (non-muscle myosin produced by activated mesenchymal cells). Cells from in-vivo explants at 16-20 weeks were fibroblast-like, with predominant vimentin expression and undetectable levels of alpha-actin (similar to native valve). Collagen elaboration and cellular expression of MMP-13 (collagenase 3) were evident in vitro at 14 days. In-vivo explants had increased collagen accumulation and strong MMP-13 expression at 4-8 weeks, but less activation (decreased expression of SMemb) and patchy endothelial cells at 16-20 weeks. Moreover, the ECM architecture of 16- to 20-week explanted TEHV resembled that of native valves. CONCLUSION: Cell phenotype and ECM in TEHV prepared in vitro and implanted in vivo are dynamic, and reflect the ability of a vital tissue to remodel and, potentially, to grow.
BACKGROUND AND AIM OF THE STUDY: Contemporary tissue valves are non-viable, and unable to grow, repair or remodel. It was postulated that tissue-engineered heart valves (TEHV) fabricated from autologous cells and a biodegradable scaffold could yield a dynamic progression of cell phenotype and extracellular matrix (ECM), in vitro and in vivo, and ultimately recapitulate native valve microscopic architecture. METHODS: Trileaflet valve constructs were fabricated from poly-4-hydroxybutyrate-coated polyglycolic acid seeded with ovine endothelial and carotid artery medial cells, cultured in vitro for 4-14 days in a pulse duplicator, implanted as pulmonary valves in five lambs, and explanted at 4-20 weeks. ECM composition and collagen architecture were examined by histology (including Movat pentachrome stain and picrosirius red under polarized light), and cell phenotype by immunohistochemistry. RESULTS: Cells from in-vitro constructs (14 days) were activated myofibroblasts, with strong expression of alpha-actin (microfilaments), vimentin (intermediate filaments) and SMemb (non-muscle myosin produced by activated mesenchymal cells). Cells from in-vivo explants at 16-20 weeks were fibroblast-like, with predominant vimentin expression and undetectable levels of alpha-actin (similar to native valve). Collagen elaboration and cellular expression of MMP-13 (collagenase 3) were evident in vitro at 14 days. In-vivo explants had increased collagen accumulation and strong MMP-13 expression at 4-8 weeks, but less activation (decreased expression of SMemb) and patchy endothelial cells at 16-20 weeks. Moreover, the ECM architecture of 16- to 20-week explanted TEHV resembled that of native valves. CONCLUSION: Cell phenotype and ECM in TEHV prepared in vitro and implanted in vivo are dynamic, and reflect the ability of a vital tissue to remodel and, potentially, to grow.
Authors: George C Engelmayr; Lorenzo Soletti; Sarah C Vigmostad; Stephanus G Budilarto; William J Federspiel; Krishnan B Chandran; David A Vorp; Michael S Sacks Journal: Ann Biomed Eng Date: 2008-02-06 Impact factor: 3.934
Authors: Benedikt Weber; Maximilian Y Emmert; Roman Schoenauer; Chad Brokopp; Laura Baumgartner; Simon P Hoerstrup Journal: Semin Immunopathol Date: 2011-01-29 Impact factor: 9.623
Authors: Salma Ayoub; Giovanni Ferrari; Robert C Gorman; Joseph H Gorman; Frederick J Schoen; Michael S Sacks Journal: Compr Physiol Date: 2016-09-15 Impact factor: 9.090
Authors: Nafiseh Masoumi; Aurélie Jean; Jeffrey T Zugates; Katherine L Johnson; George C Engelmayr Journal: J Biomed Mater Res A Date: 2012-07-24 Impact factor: 4.396
Authors: Paolo Poggio; Rachana Sainger; Emanuela Branchetti; Juan B Grau; Eric K Lai; Robert C Gorman; Michael S Sacks; Alessandro Parolari; Joseph E Bavaria; Giovanni Ferrari Journal: Cardiovasc Res Date: 2013-03-12 Impact factor: 10.787
Authors: Virna L Sales; Bret A Mettler; George C Engelmayr; Elena Aikawa; Joyce Bischoff; David P Martin; Alexis Exarhopoulos; Marsha A Moses; Frederick J Schoen; Michael S Sacks; John E Mayer Journal: Tissue Eng Part A Date: 2010-01 Impact factor: 3.845